Boston Scientific (NYSE:BSX) Reaches New 12-Month Low on Insider Selling

Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low during mid-day trading on Wednesday following insider selling activity. The company traded as low as $77.86 and last traded at $75.5250, with a volume of 8794500 shares changing hands. The stock had previously closed at $91.62.

Specifically, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Analysts Set New Price Targets

Several research analysts have weighed in on BSX shares. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Morgan Stanley lowered their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $131.00 to $112.00 and set a “buy” rating for the company in a research report on Thursday. Wells Fargo & Company dropped their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.32.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat Wall Street: Boston Scientific reported $0.80 EPS and $5.29B in sales (sales +15.9%), showing solid underlying growth that supports the company’s long-term story. PR: Q4 results
• Positive Sentiment: Analysts still mostly constructive: Many firms kept buy/overweight ratings and continue to model meaningful upside even after trimming forecasts — that backing can attract buyers after the drop. Benzinga: analysts cutting forecasts
• Neutral Sentiment: Planned board departure announced — a governance change (long‑serving director stepping down) that is notable but not an operational shock. TipRanks: board departure
• Neutral Sentiment: Unusual options activity and heavy put buying increased volatility — option flows amplified the move and can accelerate selloffs or rebounds depending on market makers’ hedging. Barchart: options activity
• Negative Sentiment: Soft 2026 guidance and underperformance in electrophysiology: management gave a cautious revenue/quarterly outlook and flagged weaker EP sales, which triggered the earlier large selloff as it reset near-term growth expectations. Reuters: cautious outlook
• Negative Sentiment: Multiple price-target cuts: several banks trimmed targets (some steeply) after the print — that lowers analyst floor and can weigh on recovery momentum. Benzinga: PT cuts
• Negative Sentiment: New investor class-action inquiry: Levi & Korsinsky announced an investigation into BSX related to the Feb. 4 results, which is a legal overhang until resolved. Newsfile: securities probe
• Negative Sentiment: CEO insider sale disclosed (large block sold in early Feb.) — raises near‑term sentiment concerns even if not unusual for executives. SEC filing: insider sale

Boston Scientific Trading Up 2.8%

The company has a market cap of $115.04 billion, a P/E ratio of 40.00, a price-to-earnings-growth ratio of 1.33 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average price is $93.90 and its 200-day moving average price is $98.98.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the business earned $0.70 EPS. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC boosted its stake in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. Belpointe Asset Management LLC lifted its holdings in shares of Boston Scientific by 119.4% in the second quarter. Belpointe Asset Management LLC now owns 5,048 shares of the medical equipment provider’s stock worth $542,000 after buying an additional 2,747 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Boston Scientific by 8.0% in the second quarter. Venturi Wealth Management LLC now owns 8,866 shares of the medical equipment provider’s stock valued at $952,000 after acquiring an additional 654 shares during the period. REAP Financial Group LLC grew its stake in Boston Scientific by 179.1% during the second quarter. REAP Financial Group LLC now owns 494 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 317 shares in the last quarter. Finally, NBT Bank N A NY increased its holdings in Boston Scientific by 4.1% during the 2nd quarter. NBT Bank N A NY now owns 3,842 shares of the medical equipment provider’s stock worth $413,000 after acquiring an additional 153 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.